Germany
Japan
United Kingdom
China
Biotinylated Anti-Human IL-17E Rabbit Polyclonal Antibody
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | E.coli derived Recombinant Human IL-17E |
Antibodies
Download
Rabbit Polyclonal H3K9/14ac Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K9/14ac antibody: histone H3 acetylated at lysines 9 and 14 (H3K9/14ac), using a KLH-conjugated synthetic peptide. |
USD 428.00
In Stock
Rabbit Polyclonal H3K9me2 Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K9me2 antibody: the region of histone H3 containing the dimethylated lysine 9 (H3K9me2), using a KLH-conjugated synthetic peptide. |
USD 428.00
In Stock
Rabbit Polyclonal H3K27me3S28p Antibody
| Applications | Dot, ELISA, IF, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K27me3S28p antibody: histone H3 containing the trimethylated lysine 27 and the phosphorylated serine 28 (H3K27me3S28p), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3S10p Antibody
| Applications | Dot, ELISA, IF, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3S10p antibody: histone H3 containing the phosphorylated serine 10 (H3S10p), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3K27me3 Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K27me3 antibody: against histone H3, trimethylated at lysine 27 (H3K27me3), using a KLH-conjugated synthetic peptide. |
TGF beta 1 (TGFB1) mouse monoclonal antibody, clone TB21, Azide Free
| Applications | ELISA, FN, IHC, WB |
| Reactivities | Human, Sheep |
| Conjugation | Unconjugated |
Rabbit Polyclonal H3K36me2 Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K36me2 antibody: histone H3 containing the dimethylated lysine 36 (H3K36me2), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3K4me2 Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K4me2 antibody: histone H3 containing the dimethylated lysine 4 (H3K4me2), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3K79me2 Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K79me2 antibody: the region of histone H3 containing the dimethylated lysine 79 (H3K79me2), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3K18ac Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human, Mouse, Broad |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K18ac antibody: the region of histone H3 containing the acetylated lysine 18 (H3K18ac), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3R17me2(asym)K18ac Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human, Mouse, Broad |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3R17me2(asym)K18ac antibody: the region of histone H3 containing the asymmetrically dimethylated R17 and the acetylated lysine 18 (H3R17me2(asym)K18ac), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H4K5,8,12ac Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human, Mouse, Broad |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H4K5,8,12ac antibody: the region of histone H4 containing the acetylated lysines 5, 8 and 12 (H4K5,8,12ac), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H4K20me3 Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H4K20me3 antibody: the region of histone H4 containing the trimethylated lysine 20 (H4K20me3), using a KLH-conjugated synthetic peptide. |
USD 750.00
In Stock
Rabbit Polyclonal H3K9me1 Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K9me1 antibody: histone H3 containing the monomethylated lysine 9 (H3K9me1), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3K9acS10p Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K9acS10p antibody: histone H3 containing the acetylated lysine 9 and the phosphorylated serine 10 (H3K9acS10p), using a KLH-conjugated synthetic peptide |
Rabbit Polyclonal H3K9me3S10p Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K9me3S10p antibody: histone H3 containing trimethylated lysine 9 and the phosphorylated serine 10 (H3K9me3S10p), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3K4me1 Antibody
| Applications | Dot, ELISA, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K4me1 antibody: histone H3 containing the monomethylated lysine 4 (H3K4me1), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3K27me1 Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K27me1 antibody: histone H3 containing the monomethylated lysine 27 (H3K27me1), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3K27me2 Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K27me2 antibody: the histone H3, dimethylated at lysine 27 (H3K27me2), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3K9me3 Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K9me3 antibody: the region of histone H3 containing the trimethylated lysine 9 (H3K9me3), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3K36me1 Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3K36me1 antibody: histone H3 containing the monomethylated lysine 36 (H3K36me1), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H3S10p Antibody
| Applications | Dot, ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H3S10p antibody: histone H3 containing the phosphorylated serine 10 (H3S10p), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal LSD1 Antibody
| Applications | ELISA, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-LSD1 antibody: human LSD1 (Lysine-specific demethylase 1), using a KLH-conjugated synthetic peptide from the inner part of the protein. |
Rabbit Polyclonal H2BK12ac Antibody
| Applications | Dot, ELISA, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H2BK12ac antibody: the region of histone H2B containing the acetylated lysine 12 (H2BK12ac), using a KLH-conjugated synthetic peptide. |
Rabbit Polyclonal H2BK15ac Antibody
| Applications | Dot, ELISA, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | The immunogen for anti-H2BK15ac antibody: the region of histone H2B containing the acetylated lysine 15 (H2BK15ac), using a KLH-conjugated synthetic peptide. |
Active filters
Reactivities
- Human
Applications
- ELISA
Filter by
Target Symbol
- UCHL1 (124)
- IL6 (113)
- LCN2 (112)
- GFAP (106)
- IL1RL1 (105)
- IL17A (90)
- S100A8/A9 (87)
- D-DIMER (81)
- SAA1 (81)
- MPO (80)
- FABP3 (68)
- MYBPC3 (63)
- REG1A (62)
- NEFL (49)
- H3C1 (37)
- IGG4 (37)
- AMH (32)
- PDCD1 (26)
- CD80 (25)
- MAPT (25)
- NPPB (24)
- NPPA (22)
- PON1 (22)
- CD274 (21)
- POMC (21)
- F13A1 (20)
- S100B (20)
- TNF (20)
- BRAF (19)
- EGFR (18)
- PDYN (18)
- FOLH1 (17)
- B2M (16)
- EDN1 (16)
- FSHB (15)
- MUC1 (15)
- CD5 (14)
- EGF (14)
- FN1 (14)
- GCG (14)
- IL2 (14)
- PENK (14)
- TP63 (14)
- CALCA (13)
- CD1C (13)
- CD44 (13)
- CSF2 (13)
- EFNA2 (13)
- MSMB (13)
- PTH (13)
- TLE1 (13)
- IFNG (12)
- EPHX1 (11)
- KLK8 (11)
- NME1 (11)
- S100A1 (11)
- SERPINB3 (11)
- ADCYAP1 (10)
- AKT1 (10)
- CCL2 (10)
- CXCL8 (10)
- ERG (10)
- IL16 (10)
- INS (10)
- MAP2K1 (10)
- OTUB1 (10)
- AFP (9)
- AGT (9)
- CA12 (9)
- CCR5 (9)
- ENG (9)
- H4-16 (9)
- JUN (9)
- LDLRAP1 (9)
- PARVA (9)
- PRKCE (9)
- TMEM173 (9)
- ALDH1L1 (8)
- AVP (8)
- CCL3 (8)
- CD33 (8)
- CD4 (8)
- FGFR2 (8)
- MSLN (8)
- PIK3AP1 (8)
- PSMD2 (8)
- SMS (8)
- SOX17 (8)
- TAC1 (8)
- TIMP2 (8)
- TP53 (8)
- WFDC2 (8)
- APP (7)
- BRCA1 (7)
- FGF2 (7)
- GH1 (7)
- HES1 (7)
- HPGD (7)
- IAPP (7)
- IKZF3 (7)
Antibody Hosts
Isotypes
Clonalities
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (40)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (17)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (12)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (9)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (7)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (5)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (5)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (4)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (4)
- This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- Phospho-specific (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original mouse scFv format for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Assay Platforms
Families
- Druggable Genome (2328)
- Secreted Protein (1103)
- Transmembrane (716)
- ES Cell Differentiation/IPS (409)
- Transcription Factors (289)
- Protease (243)
- Protein Kinase (156)
- Stem cell - Pluripotency (107)
- Adult stem cells (56)
- Embryonic stem cells (44)
- Cancer stem cells (35)
- Induced pluripotent stem cells (31)
- Stem cell relevant signaling - JAK/STAT signaling pathway (25)
- Stem cell relevant signaling - DSL/Notch pathway (23)
- GPCR (18)
- Phosphatase (17)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (11)
- Ion Channels: Other (9)
- P450 (8)
- Stem cell relevant signaling - Wnt Signaling pathway (7)
- Nuclear Hormone Receptor (6)
- Ion Channels: Transient receptor potential (3)
- Ion Channels: Cyclic nucleotide gated (1)
- Ion Channels: Potassium (1)
- Ion Channels: Sodium (1)
Pathways
- Cytokine-cytokine receptor interaction (523)
- Pathways in cancer (361)
- Jak-STAT signaling pathway (258)
- Hematopoietic cell lineage (227)
- Toll-like receptor signaling pathway (220)
- MAPK signaling pathway (199)
- Hypertrophic cardiomyopathy (HCM) (197)
- NOD-like receptor signaling pathway (169)
- Metabolic pathways (167)
- Graft-versus-host disease (164)
- Chemokine signaling pathway (154)
- Prion diseases (145)
- Focal adhesion (141)
- Cytosolic DNA-sensing pathway (133)
- Parkinson's disease (130)
- T cell receptor signaling pathway (129)
- Prostate cancer (119)
- Regulation of actin cytoskeleton (115)
- Cell adhesion molecules (CAMs) (107)
- ErbB signaling pathway (107)
- Melanoma (105)
- Colorectal cancer (98)
- Systemic lupus erythematosus (98)
- Pancreatic cancer (95)
- Bladder cancer (94)
- Endometrial cancer (91)
- Glioma (91)
- Dilated cardiomyopathy (87)
- Natural killer cell mediated cytotoxicity (87)
- PPAR signaling pathway (87)
- Chronic myeloid leukemia (82)
- Neurotrophin signaling pathway (81)
- Non-small cell lung cancer (80)
- Amyotrophic lateral sclerosis (ALS) (79)
- Fc epsilon RI signaling pathway (75)
- TGF-beta signaling pathway (75)
- Alzheimer's disease (73)
- Renal cell carcinoma (71)
- Acute myeloid leukemia (69)
- Apoptosis (68)
- Insulin signaling pathway (68)
- Progesterone-mediated oocyte maturation (68)
- Allograft rejection (65)
- GnRH signaling pathway (65)
- Endocytosis (63)
- Type I diabetes mellitus (61)
- Gap junction (57)
- Autoimmune thyroid disease (55)
- Adipocytokine signaling pathway (54)
- B cell receptor signaling pathway (54)
- Vascular smooth muscle contraction (54)
- Neuroactive ligand-receptor interaction (52)
- Thyroid cancer (50)
- Cell cycle (49)
- Small cell lung cancer (49)
- RIG-I-like receptor signaling pathway (46)
- mTOR signaling pathway (46)
- Complement and coagulation cascades (45)
- Epithelial cell signaling in Helicobacter pylori infection (44)
- Long-term depression (44)
- Wnt signaling pathway (44)
- Melanogenesis (43)
- Fc gamma R-mediated phagocytosis (42)
- Long-term potentiation (41)
- p53 signaling pathway (38)
- ECM-receptor interaction (36)
- Adherens junction (35)
- Oocyte meiosis (35)
- Tight junction (34)
- Type II diabetes mellitus (33)
- VEGF signaling pathway (33)
- Viral myocarditis (33)
- Asthma (30)
- Axon guidance (29)
- Antigen processing and presentation (28)
- Leukocyte transendothelial migration (27)
- Dorso-ventral axis formation (25)
- Glycolysis / Gluconeogenesis (25)
- Huntington's disease (25)
- Calcium signaling pathway (24)
- Metabolism of xenobiotics by cytochrome P450 (22)
- Proteasome (22)
- Cysteine and methionine metabolism (21)
- Purine metabolism (21)
- Arginine and proline metabolism (20)
- Pathogenic Escherichia coli infection (19)
- Ubiquitin mediated proteolysis (19)
- Regulation of autophagy (18)
- Notch signaling pathway (17)
- Basal cell carcinoma (16)
- Glutathione metabolism (16)
- Pyrimidine metabolism (15)
- Nitrogen metabolism (13)
- Tyrosine metabolism (12)
- Arachidonic acid metabolism (11)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (11)
- Cardiac muscle contraction (11)
- Drug metabolism - cytochrome P450 (10)
- Maturity onset diabetes of the young (10)
- Tryptophan metabolism (10)
- beta-Alanine metabolism (10)
- Fatty acid metabolism (9)
- Histidine metabolism (9)
- Homologous recombination (9)
- Lysosome (9)
- One carbon pool by folate (9)
- Primary immunodeficiency (9)
- Pyruvate metabolism (9)
- RNA degradation (9)
- ABC transporters (8)
- Citrate cycle (TCA cycle) (8)
- Hedgehog signaling pathway (8)
- Nucleotide excision repair (8)
- Folate biosynthesis (7)
- Mismatch repair (7)
- Renin-angiotensin system (7)
- Retinol metabolism (7)
- Spliceosome (7)
- Valine (7)
- leucine and isoleucine degradation (7)
- Base excision repair (6)
- N-Glycan biosynthesis (6)
- Propanoate metabolism (6)
- Starch and sucrose metabolism (6)
- Biosynthesis of unsaturated fatty acids (5)
- Butanoate metabolism (5)
- Cyanoamino acid metabolism (5)
- DNA replication (5)
- Linoleic acid metabolism (5)
- Lysine degradation (5)
- Nicotinate and nicotinamide metabolism (5)
- Non-homologous end-joining (5)
- Phenylalanine metabolism (5)
- Porphyrin and chlorophyll metabolism (5)
- Vibrio cholerae infection (5)
- Caffeine metabolism (4)
- Fructose and mannose metabolism (4)
- Glycerolipid metabolism (4)
- Oxidative phosphorylation (4)
- Pentose phosphate pathway (4)
- Alanine (3)
- Aminoacyl-tRNA biosynthesis (3)
- Olfactory transduction (3)
- Riboflavin metabolism (3)
- Ribosome (3)
- SNARE interactions in vesicular transport (3)
- Taste transduction (3)
- aspartate and glutamate metabolism (3)
- Amino sugar and nucleotide sugar metabolism (2)
- Ascorbate and aldarate metabolism (2)
- Drug metabolism - other enzymes (2)
- Ether lipid metabolism (2)
- Glycine (2)
- Limonene and pinene degradation (2)
- Primary bile acid biosynthesis (2)
- alpha-Linolenic acid metabolism (2)
- serine and threonine metabolism (2)
- Androgen and estrogen metabolism (1)
- C21-Steroid hormone metabolism (1)
- Fatty acid biosynthesis (1)
- Fatty acid elongation in mitochondria (1)
- Galactose metabolism (1)
- Glycerophospholipid metabolism (1)
- Inositol phosphate metabolism (1)
- Lysine biosynthesis (1)
- Methane metabolism (1)
- Other glycan degradation (1)
- Pentose and glucuronate interconversions (1)
- Phenylalanine (1)
- Phosphatidylinositol signaling system (1)
- Selenoamino acid metabolism (1)
- Sphingolipid metabolism (1)
- Ubiquinone and other terpenoid-quinone biosynthesis (1)
- Vitamin B6 metabolism (1)
- tyrosine and tryptophan biosynthesis (1)